Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Barclays Downgrades Whitbread To Equal Weight

Fri, 04th Dec 2015 09:33

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
BARCLAYS CUTS WHITBREAD TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 5200 PENCE
----------
DEUTSCHE BANK RAISES MEGGITT PRICE TARGET TO 400 (375) PENCE - 'HOLD'
----------
DEUTSCHE BANK RAISES BAE SYSTEMS PRICE TARGET TO 505 (485) PENCE - 'HOLD'
----------
CITIGROUP CUTS INMARSAT TO 'NEUTRAL' ('BUY') - TARGET 1150 PENCE
----------
JPMORGAN RAISES SAGE GROUP TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 670 (500) PENCE
----------
FTSE 250
----------
Cantor Ups JD Sports Fashion Target To 1,200p From 980p, Keeps Buy
----------
Investec Ups JD Sports Fashion Target To 1,100p From 1,040p, Keeps Buy
----------
LIBERUM RAISES BREWIN DOLPHIN HLDGS PRICE TARGET TO 337 (285) PENCE - 'BUY'
----------
Liberum Upgrades John Wood Group To Hold From Sell, Target At 542p
----------
Liberum Upgrades Petrofac To Buy From Hold, Target At 1,302p
----------
Liberum Upgrades Hunting To Hold From Sell, Target At 311p
----------
Liberum Upgrades AMEC Foster Wheeler To Hold From Sell, Target At 476p
----------
HSBC CUTS LANCASHIRE HLDGS TO 'HOLD' ('BUY') - TARGET 680 (715) PENCE
----------
JEFFERIES RAISES TATE & LYLE PRICE TARGET TO 680 (660) PENCE - 'BUY'
----------
JEFFERIES RAISES GREENE KING PRICE TARGET TO 940 (840) PENCE - 'HOLD'
----------
SOCGEN RAISES ICAP PRICE TARGET TO 530 (505) PENCE - 'HOLD'
----------
DEUTSCHE BANK CUTS COBHAM TO 'SELL' ('HOLD') - TARGET 265 PENCE
----------
UBS RAISES BEAZLEY PRICE TARGET TO 376 (326) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES THOMAS COOK PRICE TARGET TO 104 (100) PENCE - 'SELL'
----------
JPMORGAN RAISES GREENE KING PRICE TARGET TO 1050 (950) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES HALMA PRICE TARGET TO 700 (615) PENCE - 'UNDERWEIGHT'
----------
JPMORGAN RAISES DS SMITH PRICE TARGET TO 460 (440) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES SPIRAX-SARCO PRICE TARGET TO 3250 (3150) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS BODYCOTE PRICE TARGET TO 500 (520) PENCE - 'UNDERWEIGHT'
----------
MAIN MARKET AND AIM
----------
JPMORGAN CUTS FENNER PRICE TARGET TO 140 (150) PENCE - 'UNDERWEIGHT'
----------
Invectec Lifts Ryanair Holdings Target To EUR17.00 From EUR16.00, Keeps Buy
----------
Panmure Gordon Cuts Escher Group Target To 367p From 479p
----------
PANMURE CUTS MIDATECH PHARMA PRICE TARGET TO 417 (420) PENCE - 'BUY'
----------
N+1 Singer Cuts Iomart Group To Hold From Buy, Target At 297p
----------
Liberum Upgrades Lamprell To Buy From Hold, Target At 170p
----------
JEFFERIES RAISES ASOS PRICE TARGET TO 3600 (3500) PENCE - 'HOLD'
----------
GOLDMAN CUTS GENEL ENERGY TO 'NEUTRAL' ('BUY') - TARGET 333 (677) PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2018 11:02

Midatech Pharma 2017 Loss Narrows On Costs And Impairments Fall

LONDON (Alliance News) - Midatech Pharma PLC said Monday its 2017 loss narrowed on lower costs and reduced impairments as its approaches 2018 with a number of key "inflection" points for

Read more
15 Mar 2018 12:36

Midatech Pharma CEO Phillips To Step Down, COO Cook Steps Up

LONDON (Alliance News) - Pharmaceutical firm Midatech Pharma PLC said Thursday its Chief Executive Jim Phillips will leave the company after five years at the who is departing

Read more
22 Nov 2016 13:29

Midatech Pharma receives upfront access fee

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop

Read more
15 Nov 2016 12:04

Midatech Pharma chooses MTR104 for liver cancer treatment

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l

Read more
31 Oct 2016 09:39

BROKER RATINGS SUMMARY: HSBC Raises IAG To Hold From Reduce

Read more
11 Oct 2016 10:30

Midatech To Raise GBP14 Million Via Placing And Open Offer (ALLISS)

Read more
30 Sep 2016 08:41

Midatech Says Trials Of Drug Using Its Gold Nanoparticles Commence

Read more
2 Sep 2016 12:07

Midatech Pharma's revenues increases due to US sales

(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s

Read more
7 Jul 2016 09:05

Midatech-Cardiff University Collaboration Gets Diabetes Grant

Read more
27 Jun 2016 11:29

Midatech Pharma Issues Final Shares To Settle Q Chip Acquisition (ALLISS)

Read more
18 May 2016 09:39

Midatech Signals Further Focus On "Better Suited" Oncology Treatments

Read more
11 May 2016 08:49

Midatech Pharma Trading Ahead Of Expectations On Strong Revenue Growth

Read more
26 Apr 2016 09:27

Midatech Pharma Gets Positive Data From Q-Octreotide Trial

Read more
21 Apr 2016 07:55

Midatech Pharma Sees Positive Dosing Data In Uveitis Programme

Read more
13 Apr 2016 08:24

Midatech Loss Widens On Acquisition Costs, But Revenue Surges

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.